Deutsch English Français

Contact

EP1954281

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...

Extract from the Register of European Patents

EP About this file: EP1954281

EP1954281 - CANCER TREATMENT METHOD [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 13.01.2012 Database last updated on 01.04.2026
Most recent event Tooltip	13.01.2012	No opposition filed within time limit	published on 15.02.2012 [2012/07]
Applicant(s)	For all designated states GlaxoSmithKline LLC One Franklin Plaza 200 North 16th Street Philadelphia, PA 19102 / US
	[N/P]
Former [2010/09]	For all designated states GlaxoSmithKline LLC One Franklin Plaza 200 North 16th Street Philadelphia, PA 19102 / US
Former [2008/33]	For all designated states SmithKline Beecham Corporation One Franklin Plaza P.O. Box 7929 Philadelphia, PA 19101 / US
Inventor(s)	01 / PANDITE, Arundathy Nirmalini GlaxoSmithKline c/o Corporate Intellectual Property Department Five Moore Drive PO Box 13398 Research Triangle Park, NC 27709-3398 / US
	02 / WHITEHEAD, Bonnie F. GlaxoSmithKline c/o Corporate Intellectual Property Department Five Moore Drive Po Box 13398 Research Triangle Park, NC 27709-3398 / US
	03 / HO, Peter T.C. GlaxoSmithKline c/o Corporate Intellectual Property Department 1250 South Collegeville Road Po Box 5089 Collegeville, PA 19426 / US
	04 / SUTTLE, Albert Benjamin GlaxoSmithKline c/o Corporate Intellectual Property Department Five Moore Drive PO Box 13398 Research Triangle Park, NC 27709-3398 / US
	[2008/33]
Representative(s)	Learoyd, Stephanie Anne GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road Brentford, Middlesex TW8 9GS / GB
	[N/P]
Former [2008/33]	Learoyd, Stephanie Anne GlaxoSmithKline Corporate Intellectual Property (CN9.25.1) 980 Great West Road Brentford, Middlesex TW8 9GS / GB
Application number, filing date	06838636.6	29.11.2006
	[2008/33]
	WO2006US45777
Priority number, date	US20050740308P	29.11.2005 Original published format: US 740308 P
	[2008/33]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2007064753
	Date:	07.06.2007
	Language:	EN
	[2007/23]
	Type:	A2 Application without search report
	No.:	EP1954281
	Date:	13.08.2008
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 07.06.2007 takes the place of the publication of the European patent application.
	[2008/33]
	Type:	B1 Patent specification
	No.:	EP1954281
	Date:	09.03.2011
	Language:	EN
	[2011/10]
Search report(s)	International search report - published on:	EP	29.11.2007
Classification	IPC:	A61K31/506, A61P35/00	[2008/33]
	CPC:	A61K31/506 (EP,US); A61P35/00 (EP)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2008/33]
Extension states	AL	Not yet paid
	BA	Not yet paid
	HR	29.04.2008
	MK	Not yet paid
	RS	Not yet paid
Title	German:	KREBSBEHANDLUNGSVERFAHREN	[2008/33]
	English:	CANCER TREATMENT METHOD	[2008/33]
	French:	PROCEDE DE TRAITEMENT DU CANCER	[2008/33]
Entry into regional phase	29.04.2008	National basic fee paid
	29.04.2008	Designation fee(s) paid
	29.04.2008	Examination fee paid
Examination procedure	29.04.2008	Amendment by applicant (claims and/or description)
	29.04.2008	Examination requested [2008/33]
	17.03.2010	Despatch of a communication from the examining division (Time limit: M04)
	16.07.2010	Reply to a communication from the examining division
	17.08.2010	Despatch of a communication from the examining division (Time limit: M04)
	23.09.2010	Reply to a communication from the examining division
	28.10.2010	Communication of intention to grant the patent
	18.01.2011	Fee for grant paid
	18.01.2011	Fee for publishing/printing paid
Divisional application(s)	EP10194774.5 / EP2380572
Opposition(s)	12.12.2011	No opposition filed within time limit [2012/07]
Fees paid	Renewal fee
	07.11.2008	Renewal fee patent year 03
	06.11.2009	Renewal fee patent year 04
	22.10.2010	Renewal fee patent year 05
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[X] SCHLEUCHER N., CANCER ABSTRACTS & SUMMARIES, vol. 5, no. 13, 2004, NEW ORLEANS LA, pages 1 - 12, XP002426649, ISSN: 1535-2404, Retrieved from the Internet [retrieved on 20070326]
		[X] KAELIN W G: "von Hippel-Lindau-associated malignancies: Mechanisms and therapeutic opportunities", DRUG DISCOVERY TODAY: DISEASE MECHANISMS, ELSEVIER, vol. 2, no. 2, July 2005 (2005-07-01), pages 225 - 231, XP004983105, ISSN: 1740-6765 DOI: http://dx.doi.org/10.1016/j.ddmec.2005.04.003
		[X] WAKELEE HEATHER A ET AL: "TARGETING ANGIOGENESIS WITH VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SMALL-MOLECULE INHIBITORS: NOVEL AGENTS WITH POTENTIAL IN LUNG CANCER", CLINICAL LUNG CANCER, CANCER INFORMATION GROUP, DALLAS, TX, US, vol. 7, no. 1, September 2005 (2005-09-01), pages S31 - S38, XP008076798, ISSN: 1525-7304
		[X] REDDY G K: "EARLY CLINICAL DATA WITH SMALL-MOLECULE VASCULAR ENDOTHELIAL GROWTH FACTOR TYROSINE KINASE RECEPTOR INHIBITORS", CLINICAL LUNG CANCER, CANCER INFORMATION GROUP, DALLAS, TX, US, vol. 6, no. 2, September 2004 (2004-09-01), pages 74 - 76, XP008068254, ISSN: 1525-7304
		[X] COLLINS TIMOTHY S ET AL: "Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.", SEMINARS IN ONCOLOGY FEB 2005, vol. 32, no. 1, February 2005 (2005-02-01), pages 61 - 68, XP008076800, ISSN: 0093-7754
		[X] BOIGE V ET AL: "THERAPEUTIC STRATEGIES USING VEGF INHIBITORS IN COLORECTAL CANCER", BULLETIN DU CANCER, EDITIONS SCIENTIFIQUES ELSEVIER, PARIS, FR, vol. 92, 2005, pages S29 - S36, XP008076804, ISSN: 0007-4551
		[X] PENLAND S K ET AL: "COMBINING ANTI-VEGF APPROACHES WITH OXALIPLATIN IN ADVANCED COLORECTAL CANCER", CLINICAL COLORECTAL CANCER, XX, US, vol. 4, no. 2, 2004, pages S74 - S80, XP008076801, ISSN: 1533-0028
		[X] HURWITZ ET AL.: "Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors", JOURNAL OF CLINICAL ONCOLOGY, 2005 ASCO ANNUAL MEETING PROCEEDINGS, vol. 23, no. 16S, 1 June 2005 (2005-06-01), pages A3012, XP002446369
		[X] SHAHEEN P E ET AL: "EMERGING DRUGS FOR RENAL CELL CARCINOMA", EXPERT OPINION ON EMERGING DRUGS, ASHLEY PUBLICATIONS, GB, vol. 10, no. 4, 2005, pages 773 - 795, XP008076805, ISSN: 1472-8214 DOI: http://dx.doi.org/10.1517/14728214.10.4.773
		[X] HUTSON THOMAS E ET AL: "A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma.", CLINICAL GENITOURINARY CANCER MAR 2006, vol. 4, no. 4, March 2006 (2006-03-01), pages 296 - 298, XP008076820, ISSN: 1558-7673
		[X] BAKA S ET AL: "A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis", EXPERT OPINION ON THERAPEUTIC TARGETS, ASHLEY PUBLICATIONS, LONDON, GB, vol. 10, no. 6, 2006, pages 867 - 876, XP008080403, ISSN: 1472-8222 DOI: http://dx.doi.org/10.1517/14728222.10.6.867
		[X] WAGSTAFF J: "New horizons in the treatment of renal cell cancer", ANNALS OF ONCOLOGY 2006 UNITED KINGDOM, vol. 17, no. SUPPLO. 10, 2006, pages x19 - x22, XP008076802, ISSN: 0923-7534 1569-8041 [X] 1-8,24 * page 9 - page 10; table 3 * DOI: http://dx.doi.org/10.1093/annonc/mdl230
		[X] DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; September 2005 (2005-09-01), WHISENANT JONATHAN ET AL: "Anti-angiogenic strategies in gastrointestinal malignancies.", XP002450910, Database accession no. NLM16107244 [X] 1-8,24 * abstract * * table 1 *
		[X] CURRENT TREATMENT OPTIONS IN ONCOLOGY SEP 2005, vol. 6, no. 5, September 2005 (2005-09-01), pages 411 - 421, ISSN: 1527-2729 * abstract * * page S35, column 1, paragraph 3 *
		[X] WORDEN BRIAN ET AL: "Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma.", CANCER RESEARCH 15 AUG 2005, vol. 65, no. 16, 15 August 2005 (2005-08-15), pages 7071 - 7080, XP002450907, ISSN: 0008-5472 [X] 1-8,24 * page 75, column 2, paragraph 2 - column 3, paragraph 2; table 1 * DOI: http://dx.doi.org/10.1158/0008-5472.CAN-04-0989
		[X] DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; August 2005 (2005-08-01), RHEE JAY ET AL: "Angiogenesis inhibitors in the treatment of cancer.", XP002450911, Database accession no. NLM16086656 [X] 1-7,13,24 * page 65, column 2, paragraph 5 - page 66, column 1, paragraph 1; table 4 * * abstract *
		[X] EXPERT OPINION ON PHARMACOTHERAPY AUG 2005, vol. 6, no. 10, August 2005 (2005-08-01), pages 1701 - 1711, ISSN: 1744-7666 * abstract * * page S33, column 2, paragraph 4 *
		[X] SAWA H ET AL: "HISTONE DEACETYLASE INHIBITORS SUCH AS SODIUM BUTYRATE AND TRICHOSTATIN A INHIBIT VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) SECRETION FROM HUMAN GLIOBLASTOMA CELLS", NOSHUYO BYORI - BRAIN TUMOR PATHOLOGY, NIHON NOSHUYO BYORI KENKYUKAI, NAGOYA, JP, vol. 19, no. 2, 2002, pages 77 - 81, XP009029987, ISSN: 0914-8108 [X] 1-7,13,24 * abstract *
		[X] MONK B J ET AL: "Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 96, no. 3, March 2005 (2005-03-01), pages 902 - 905, XP004757104, ISSN: 0090-8258 [X] 1-8,14,24 * abstract * DOI: http://dx.doi.org/10.1016/j.ygyno.2004.12.001
		[PX] KLEESPIES A ET AL: "CLINICAL SIGNIFICANCE OF VEGF-A, -C AND -D EXPRESSION IN ESOPHAGEAL MALIGNANCIES", ONKOLOGIE, KARGER, FREIBURG, DE, vol. 28, no. 5, 2005, pages 281 - 288, XP009080203, ISSN: 0378-584X [PX] 1-8,24 * abstract * DOI: http://dx.doi.org/10.1159/000085198
		[PX] HOTZ H G ET AL: "VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer", SURGERY, C.V. MOSBY CO., ST. LOUIS,, US, vol. 137, no. 2, February 2005 (2005-02-01), pages 192 - 199, XP004726217, ISSN: 0039-6060 [PX] 1-8,24 * the whole document * DOI: http://dx.doi.org/10.1016/j.surg.2004.07.015
		[PX] LAMMERT E ET AL: "Role of VEGF-A in Vascularization of Pancreatic Islets", CURRENT BIOLOGY, CURRENT SCIENCE,, GB, vol. 13, no. 12, 17 June 2003 (2003-06-17), pages 1070 - 1074, XP004535095, ISSN: 0960-9822 [PX] 1-8,24 * abstract * DOI: http://dx.doi.org/10.1016/S0960-9822(03)00378-6
		[PX] DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 28 June 2005 (2005-06-28), ZHI YING-HUI ET AL: "Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma.", XP002450939, Database accession no. NLM15968728 [PX] 1-8,24 * abstract * * page 21, column 2, paragraph 6; table 4 *
		[PX] WORLD JOURNAL OF GASTROENTEROLOGY : WJG 28 JUN 2005, vol. 11, no. 24, 28 June 2005 (2005-06-28), pages 3724 - 3728, ISSN: 1007-9327 * abstract *
		[A] BAEZA ET AL: "Post-Operative Adjuvant Radiochemotherapy in the Treatment of Gallbladder Cancer", INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, US, vol. 63, 1 October 2005 (2005-10-01), pages S285 - S286, XP005083493, ISSN: 0360-3016 DOI: http://dx.doi.org/10.1016/j.ijrobp.2005.07.488
	by applicant	FOLKMANN, J., J. NAT'1. CANCER INST., vol. 82, 1990, pages 4 - 6
		MUSTONEN, T. ET AL., J. CELL BIOL., vol. 129, 1995, pages 895 - 898
		FERRARA; DAVIS-SMYTH, ENDOCRINE REVIEWS, vol. 18, no. 1, 1997, pages 4 - 25
		MCMAHON, G., THE ONCOLOGIST, vol. 5, no. 90001, 2000, pages 3 - 10
		MONK B. J. ET AL.: "Gynaecologic Oncology", 2005, ACADEMIC PRESS, pages: 902 - 905
		PHARMACEUTICAL RESEARCH, vol. 3, no. 6, 1986, pages 318
		TANGJITGAMOL, S ET AL., INT. J. GYNECOL. CANCER, vol. 15, no. 4, 2005, pages 646 - 56
		MATHUR, SP ET AL., GYNECOL. ONCOL., vol. 98, no. 3, 2005, pages 467 - 83

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.